EyePoint Pharmaceuticals 관리
관리 기준 확인 2/4
EyePoint Pharmaceuticals CEO는 Jay Duker, Jan2023 에 임명되었습니다 의 임기는 1.83 년입니다. 총 연간 보상은 $ 2.92M, 21.1% 로 구성됩니다. 21.1% 급여 및 78.9% 보너스(회사 주식 및 옵션 포함). 는 $ 541.72K 가치에 해당하는 회사 주식의 0.086% 직접 소유합니다. 541.72K. 경영진과 이사회의 평균 재임 기간은 각각 1.8 년과 3.3 년입니다.
주요 정보
Jay Duker
최고 경영자
US$2.9m
총 보상
| CEO 급여 비율 | 21.1% |
| CEO 임기 | 1.8yrs |
| CEO 소유권 | 0.09% |
| 경영진 평균 재임 기간 | 1.8yrs |
| 이사회 평균 재임 기간 | 3.3yrs |
최근 관리 업데이트
Recent updates
EyePoint Pharmaceuticals: Low Price And Good Data Create An Opportunity
Nov 14Revenues Not Telling The Story For EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) After Shares Rise 52%
Oct 29
EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) Intrinsic Value Is Potentially 38% Above Its Share Price
Sep 13EyePoint Pharmaceuticals - After A Tough 2024 To Date, Is It Time To 'Buy The Dip' (Rating Upgrade)
Aug 29These Analysts Think EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) Sales Are Under Threat
Aug 15EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Just Reported Second-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
Aug 09Some Confidence Is Lacking In EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) As Shares Slide 27%
Jun 19EyePoint's Setback In NPDR Does Not Bode Well For DME (Rating Downgrade)
May 06More Unpleasant Surprises Could Be In Store For EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) Shares After Tumbling 26%
Mar 31EyePoint Pharmaceuticals: Innovating Eye Treatment, Yet A 'Hold' At This Time
Feb 20Subdued Growth No Barrier To EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) With Shares Advancing 41%
Feb 05Is EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Trading At A 28% Discount?
Jan 29Optimistic Investors Push EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Shares Up 194% But Growth Is Lacking
Dec 18These Analysts Think EyePoint Pharmaceuticals, Inc.'s (NASDAQ:EYPT) Sales Are Under Threat
Dec 13Calculating The Fair Value Of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)
May 14Optimistic Investors Push EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Shares Up 84% But Growth Is Lacking
Apr 17EyePoint Pharmaceuticals: Key Player In The Long-Acting Wet AMD Space
Aug 30Health Check: How Prudently Does EyePoint Pharmaceuticals (NASDAQ:EYPT) Use Debt?
Jul 16EyePoint Pharma announces 12-month phase 1 data for its treatment for eye disorder wAMD
Jul 15Health Check: How Prudently Does EyePoint Pharmaceuticals (NASDAQ:EYPT) Use Debt?
Mar 06CEO 보상 분석
| 날짜 | 총 보상 | 급여 | 회사 수익 |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$104m |
| Jun 30 2024 | n/a | n/a | -US$87m |
| Mar 31 2024 | n/a | n/a | -US$79m |
| Dec 31 2023 | US$3m | US$614k | -US$71m |
| Sep 30 2023 | n/a | n/a | -US$100m |
| Jun 30 2023 | n/a | n/a | -US$106m |
| Mar 31 2023 | n/a | n/a | -US$102m |
| Dec 31 2022 | US$2m | US$515k | -US$102m |
| Sep 30 2022 | n/a | n/a | -US$78m |
| Jun 30 2022 | n/a | n/a | -US$77m |
| Mar 31 2022 | n/a | n/a | -US$67m |
| Dec 31 2021 | US$3m | US$269k | -US$58m |
| Sep 30 2021 | n/a | n/a | -US$54m |
| Jun 30 2021 | n/a | n/a | -US$42m |
| Mar 31 2021 | n/a | n/a | -US$44m |
| Dec 31 2020 | US$53k | n/a | -US$45m |
| Sep 30 2020 | n/a | n/a | -US$40m |
| Jun 30 2020 | n/a | n/a | -US$52m |
| Mar 31 2020 | n/a | n/a | -US$51m |
| Dec 31 2019 | US$80k | n/a | -US$57m |
| Sep 30 2019 | n/a | n/a | -US$58m |
| Jun 30 2019 | n/a | n/a | -US$75m |
| Mar 31 2019 | n/a | n/a | -US$98m |
| Dec 31 2018 | US$27k | n/a | -US$86m |
보상 대 시장: Jay 의 총 보상 ($USD 2.92M )은 US 시장에서 비슷한 규모의 회사의 평균 수준입니다( $USD 3.18M ).
보상과 수익: 회사가 수익성이 없는 동안 Jay 의 보상이 증가했습니다.
CEO
Jay Duker (65 yo)
1.8yrs
테뉴어
US$2,915,146
보상
Dr. Jay S. Duker, M.D., co-founded Hemera Biosciences Inc. and serves as its Executive Director. He serves as Member of Retina Segment Scientific Advisory Board at Aldeyra Therapeutics, Inc. He served as C...
리더십 팀
| 이름 | 위치 | 테뉴어 | 보상 | 소유권 |
|---|---|---|---|---|
| President | 1.8yrs | US$2.92m | 0.086% $ 541.7k | |
| Executive VP & CFO | 5yrs | US$1.78m | 0.068% $ 424.9k | |
| Interim Head of R&D and Director | less than a year | US$161.67k | 0.016% $ 102.0k | |
| Senior Vice President of Manufacturing & Operations | 1.3yrs | 데이터 없음 | 데이터 없음 | |
| Chief Legal Officer & Company Secretary | 6yrs | 데이터 없음 | 데이터 없음 | |
| Chief People Officer & Senior VP of IT | 5.8yrs | 데이터 없음 | 데이터 없음 | |
| Senior VP & Chief Commercial Officer | 5.4yrs | US$1.46m | 데이터 없음 | |
| Chief Business Officer | 1.1yrs | US$1.61m | 0.019% $ 122.3k | |
| Chief Regulatory Officer | 2.7yrs | 데이터 없음 | 데이터 없음 | |
| Senior VP and Head of Development & Program Management | 1.3yrs | 데이터 없음 | 데이터 없음 | |
| Chief Medical Officer | less than a year | 데이터 없음 | 데이터 없음 | |
| CEO of AION Diagnostics Ltd | no data | US$225.94k | 데이터 없음 |
1.8yrs
평균 재임 기간
58yo
평균 연령
경험이 풍부한 관리: EYPT 의 관리팀은 경험 (평균 재직 기간 1.8 년)으로 간주되지 않으므로 새로운 팀을 추천합니다.
이사회 구성원
| 이름 | 위치 | 테뉴어 | 보상 | 소유권 |
|---|---|---|---|---|
| President | 1.3yrs | US$2.92m | 0.086% $ 541.7k | |
| Interim Head of R&D and Director | 6.1yrs | US$161.67k | 0.016% $ 102.0k | |
| CEO of AION Diagnostics Ltd | no data | US$225.94k | 데이터 없음 | |
| Independent Non-Executive Chairman | 6.4yrs | US$214.78k | 0.019% $ 117.7k | |
| Independent Director | 5.3yrs | US$171.67k | 0.014% $ 89.2k | |
| Vice Chair | 8.2yrs | US$3.74m | 0.32% $ 2.0m | |
| Co- Chairman of Scientific Advisory Board | 3.3yrs | 데이터 없음 | 데이터 없음 | |
| Member of Executive Scientific Advisory Board | 3.3yrs | 데이터 없음 | 데이터 없음 | |
| Independent Director | 2.3yrs | US$149.17k | 0.024% $ 147.7k | |
| Co-Chair of Scientific Advisory Board | 3.3yrs | 데이터 없음 | 데이터 없음 | |
| Member of Executive Scientific Advisory Board | 3.3yrs | 데이터 없음 | 데이터 없음 | |
| Member of Executive Scientific Advisory Board | 3.3yrs | 데이터 없음 | 데이터 없음 |
3.3yrs
평균 재임 기간
66yo
평균 연령
경험이 풍부한 이사회: EYPT 의 이사회는 경험(평균 재직 기간 3.3 년)으로 간주됩니다.